Objective: Isolated growth hormone deficiency (IGHD) type IB is suggested to be more probably due to alterations in the genes directly involved in the hypothalamo-pituitary axis and/or in the specific transcriptional regulation (cis-trans coupling) of the hGH-1 gene than to alterations in the gene itself. In this study we analyzed the hGH-1 gene promoter region for structural alterations and allelic variations.
Introduction
The human growth hormone (hGH)/human chorionic somatomammotropin hormone (hCSH) gene cluster is located on the long arm of chromosome 17 at bands q22-24 (1, 2). It includes five structural genes spanning 48 kb of DNA in the order: 5 0 -(hGH-1)-(hCSHP-1)-(hCSH-1)-(hGH-2)-(hCSH-2)-3 0 (Fig. 1 ). These genes show the same transcriptional orientation and are separated by intergenic regions of 6 to 13 kb in length. All five genes, including their immediate flanking regions, have been sequenced and are 91-99% sequence conserved (3) (4) (5) (6) .
Despite this high degree of sequence homology, each of these genes is expressed selectively in a tissue-specific fashion: the hGH-1 gene exclusively in somatotrope cells of the anterior pituitary gland, and the hCSH-1 and hCSH-2 genes and the hGH-2 gene in the placental syncytiotrophoblast cells (for reviews, see 7 and 8) . While hCSHP-1 was initially classified as a non-expressed pseudogene its expression in human placenta was recently demonstrated (9) .
Short stature and growth disorders caused by an insufficient growth hormone (GH) secretion are a common clinical problem. Estimates of the frequency of growth hormone deficiency (GHD) range from 1 in 4000 to 1 in 10 000 live births in different countries. Although most cases are sporadic and are believed to result from environmental insults or developmental abnormalities, 3-30% of the cases reported have an affected first-degree relative, suggesting that a significant proportion of the cases with GHD are in fact familial (10, 11) .
On a hereditary basis, four forms of isolated GHD (IGHD) were classified by Phillips (12) . Type IA, the most severe form, is autosomal recessively inherited and caused by homozygous deletions of different sizes of, and/or by homozygous substitutions and nonsense mutations or by compound heterozygosity for deletion/ mutations in, the hGH-1 gene. No GH is detectable and there is no GH response to any stimulation test.
Type IB, the most common form of IGHD, also autosomal recessive, is characterized by production of low but detectable amounts of intact GH after provocative stimuli and no deletions of the hGH-1 gene are detectable. Any alteration to the gene directly involved in the hypothalamo-pituitary axis, including the genes for growth hormone releasing hormone (GHRH) and the GHRH receptor as well as any alteration to the locus control region (13) and/or to specific transcriptional regulation of the hGH-1 gene, could theoretically produce this phenotype.
Type II, which is autosomal dominant, is characterized by production of small quantities of hGH and good response to exogenous recombinant hGH (r-hGH).
Type III is X-linked inherited and is often associated with hypogammaglobulinemia.
The regulation of hGH-1 gene transcription (for reviews see 14 and 15) is considered to be exerted by specific interactions of tissue-specific and other more ubiquitous regulatory proteins (trans-factors) which bind specific DNA sequences (cis-elements) located mainly within the immediate 5 0 -flanking promoter region. Different types of cis-trans coupling are thought to allow both tissue-specific expression and also hormonal induction or inhibition of gene transcription. It has been shown that sequence alterations in transfactors can cause low activity of transcription of different genes (14, 15) .
Since children with IGHD type IB produce small amounts of GH and respond well to exogenous r-hGH, it seems likely that alterations of trans-factors as well as of cis-elements could perturb the expression of GH and result in IGHD.
In a previous study of different tissue-specific transfactors and candidate genes influencing the hypothalamo-pituitary-peripheral tissue axis we found that retinoic acid receptor alpha, as an example of a transacting factor, has an impact on hGH-1 gene transcription (16) . To clarify the role of possible alterations to ciselements in the immediate 5 0 -flanking promoter region of the hGH-1 gene we used PCR and cycle sequencing.
Subjects
We analyzed five large families, four from Turkey and one from Great Britain, with a total of 38 individuals including 17 patients with IGHD type IB and 21 nonaffected members (Fig. 2 ) and 11 normal controls from different countries, 1 from Sweden, Holland, Germany, Italy and Hong Kong, 2 from Greece and 4 from Switzerland.
Furthermore, the data of 96 unrelated patients with IGHD type IB and of 67 normal controls from the USA were added. These subjects were not studied for all variation sites, but individually according to different points of interest. GH deficiency was diagnosed as previously reported (8, 17) . Deletions of the hGH-1 gene (IGHD type IA) were excluded by PCR amplification (18, 19) and/or by Southern blotting (17, 20) .
Methods

DNA extraction
Human genomic DNA was extracted from 5-10 ml EDTA-treated blood samples as previously described (21) .
PCR amplification
The PCR-primers were designed to specifically amplify a fragment of 2200 bp length flanking the hGH-1 promoter region from ¹1483 bp to þ737 bp as shown in Fig. 1 , and their sequences are given in Table 1 . Both the sense PCR Primer Upper 1 (sPP U1) and the antisense PCR Primer Lower 1 (asPP L1) were synthesized by Microsynth, Windisch, Switzerland.
The PCR amplifications were performed in final volumes of 100 ml containing 1 × concentrated PCR reaction buffer, 20 nmol of each dNTP, 2.5 U Taq DNApolymerase (Boehringer Mannheim GmbH, Rotkreuz, Switzerland), 0.5% dimethylsulfoxide, 25 pmol of each primer and 500 ng genomic DNA.
The PCR reaction mixtures were placed in a thermocycler (AMS Biotechnology Ltd, Oxon, UK) and first denatured at 94 ЊC for 3 min, then subjected to 30 cycles each consisting of 45 s denaturation at 94 ЊC, 45 s annealing at 68 ЊC and 2 min extension at 72 ЊC, followed by a final extension at 72 ЊC for 5 min, and finally cooled to 4 ЊC.
The PCR products were purified with the QIAquick PCR Purification Kit from Qiagen AG (Basel, Switzerland) using conditions specified by the commercial supplier, eluted in 10 mM Tris-HCl pH 8.5 and analyzed by agarose-gel electrophoresis.
Cycle sequencing
For the non-radioactive cycle sequencing, seven nested 5961  TGTTGGAGGGTGTCGGAATAGACT  68   sSPO  3752  AGGAAGAGCAAGGTTGTGGAGAT  69  sSP1a  4034  AGGTGGAGTCTTGCTCTGTTG  64  sSP2  4328  TCGGCGTGATGTGTTCTGAGT  64  sSP3a  4592  GGGTTGGTTCTCTCTAGTG  62  sSP4  4776  GGGGAGGAGGAAAGGGATAGG  66  sSP5  4980  GGTGGGAAGGGAAAGATGA  61  sSP6  5176  CCAACTCCCCGAACCACTCA  66 The 5 0 -position refers to the nucleotide sequences published by Chen et al. (6) . In the first two columns, the label and the location (with regard to the translational site) of the 22 variation sites are shown. The third column shows the nucleotides found at specific locations. Bases that correspond to the sequences published by Chen et al. (6) (as in Fig. 3 ) are in italic. The abbreviations used are 'del' for deletion and 'het.' for heterozygous. Thereafter, a list is presented indicating in more detail the frequency of each nucleotide in controls, normal and affected family members and unrelated patients. In the last two columns the frequencies of the sequence changes of all subjects analyzed are summarized and shown as a percentage. *S ¼ G:C het., M ¼ A:C het., R ¼ G:A het.
region from approximately ¹1400 bp to þ300 bp as shown in Fig. 2 . The sSP0, sSP1a, sSP2, sSP3a, sSP4, sSP5 and sSP6 were synthesized and 5 0 -DIG-labeled by MWG-Biotech, Ebersberg, Germany.
For the non-radioactive cycle sequencing of doublestranded PCR products a DIG Taq DNA Sequencing Kit for Standard and Cycle Sequencing (Boehringer Mannheim) was used.
J K Wagner and others
EUROPEAN JOURNAL OF ENDOCRINOLOGY (1997) 137
Figure 3 Representation of the variation sites within the hGH-1 gene promoter. Compared with the sequences published by Chen et al. (6) we found 22 variation sites (outlined bases) labeled from a to v. The known consensus binding sites of cis-elements are underlined and defined. The nucleotides of exons are in bold style.
Each stop-reaction (ddGTP, ddATP, ddTTP or ddCTP) was performed in a final volume of 10 ml containing 1 × concentrated reaction buffer, 3.3 ml of the appropriate ddNTP/7-deaza-dGTP termination mix, 1U Taq DNA-polymerase, 1 pmol of one 5 0 -DIG-labeled sense Sequencing Primer and 0.5 ml purified PCR product.
The sequencing reaction mixtures were placed in a thermocycler (AMS Biotechnology Ltd) and first
Allelic variations in the hGH-1 gene promoter 479 Table 3 Segregation patterns of different sequence variation sites within the five families studied.
The segregation pattern of nucleotides within the variation sites of each family is presented. In the two first columns, the family members are labeled according to the pedigrees presented in Fig. 2 denatured at 95 ЊC for 3 min, then subjected to 30 cycles each consisting of 45 s denaturation at 95 ЊC, 30 s annealing (Table 1 ) and 2 min extension at 72 ЊC, followed by a final extension at 72 ЊC for 5 min, and finally cooled to 4 ЊC.
Direct blotting electrophoresis and DIG detection
The non-radioactive labeled sequencing reactions were analyzed by using a GATC 1500 Direct Blotting Electrophoresis System (GATC GmbH, Konstanz, Germany) (22, 23) . The fragments were chemiluminescently detected as described in the provided manual/protocol using a DIG Detection Kit (Boehringer Mannheim) and exposed to X-ray film for 6 to 12 h.
Results
The members of the families F02, F04, F07, F34 and F51 presented 13, 10, 13, 8 and 12 variation sites within the hGH-1 gene promoter region, respectively. The unrelated patients revealed 13 variation sites, and furthermore 19 variation sites were found in the normal controls. Together, we detected 22 different sequence variation sites in the promoter region of the hGH-1 gene ( Fig. 3 and Table 2 ). Furthermore, in Table 3 the segregation patterns of the different variation sites within the families studied are reported.
Only one variation site ( j) affected the consensus binding site of a cis-element, namely that of the transfactor NF-1 (Fig. 3) .
All nucleotide variations found in patients were also observed in non-affected family members and/or in normal controls, except for only four variations seen in unrelated patients (Table 2) .
Discussion
Compared with the sequences published by Chen et al. (6) we found a total of 22 different sequence variation sites in the promoter region of the hGH-1 gene (see Fig. 3 and Table 2 ). The locations of these sites are of interest.
The majority, 77% (17/22), were found in the immediate 5 0 -flanking promoter region between ¹550 bp and the translational start site (þ1 bp). This region is important for transcriptional regulation and contains the cis-elements for a variety of trans-factors including NF-1, USF, SP1, Pit-1, Z-and TATA-box binding proteins.
While several of these sequence variation sites (labeled as: g, h, i, l, m, n, o and p) fall near these ciselements, only 'j' falls directly within one of them (Fig. 3) . The sequence variations at these sites, normally occurring in patients and controls, may be of importance and should be considered when interpreting promoter studies of the hGH-1 gene.
While the locations of the sequence variation sites d, e, k, q, r, s and t are 190, 78, 32, 38, 47, 49 and 83 bp distant from a consensus binding site, respectively, we cannot exclude that these changes, in one or both alleles of the hGH-1 gene promoter of individual GH-deficient patients at these sites, may perturb expression by some secondary structural changes.
Of the remaining variation sites, 14% (3/22) were located around the region of ¹1075 bp and 9% (2/22) within the first intron at the positions þ76 bp and þ219 bp.
Regarding the variation site at the NF-1 binding site (at position j) (see Fig. 3 ) it seems that heterozygous changes in this variation site may not affect the expression of pituitary gland-derived GH and that one non-mutated allele is sufficient to provide the necessary cis-trans coupling. This is supported by our finding that the variation is present in about 50% of controls (Table 2) . Interestingly, despite this high frequency in controls and affected family members, no individuals with homozygous changes for this site were found. Importantly however, although a consensus binding site of NF-I is present in the hGH-1 gene promoter region, there are, to our knowledge, no data available reporting the necessity of NF-1 for hGH-1 gene expression.
All the sequence changes found in one or both alleles of the hGH-1 gene promoter of GH-deficient patients were also observed in non-affected family members and/ or in normal controls, except for four nucleotide changes at the variation sites d, e, k and s seen in unrelated patients (Table 2) . While these data imply that no single variation (with reservation to the four exceptions mentioned) is related to GH deficiency, we cannot exclude the possibility that some combinations of variations might in concert perturb expression. Nevertheless, the molecular basis for the IGHD type IB observed in these five families analyzed can probably not be attributed to variations in the immediate 5 0 -flanking promoter region of the hGH-1 gene and the precise location(s) of the molecular defects in this disease remain(s) therefore unknown.
The data presented illustrate the heterogeneity of the hGH-1 gene promoter region, a fact that has to be borne in mind whenever transcriptional studies are performed.
